We strive to develop best-in-class therapies in our growing focus area of oncology. We work tirelessly to address the unmet needs of oncology patients, including patients with acute lymphoblastic leukemia (ALL) and pancreatic cancer, and all who support them on their journey.
Shire’s expertise in rare and difficult-to-treat cancers includes ongoing research into investigational pegylated asparaginase as a component of antineoplastic combination therapy in ALL. The company’s pipeline in oncology includes assets being developed for the treatment of metastatic pancreatic cancer, ALL, and lung cancer, as well as early stage checkpoint inhibitor and allogeneic CAR T targets.
We are deeply committed to understanding our patients’ needs and delivering resources, support, and transformative therapies to improve the lives of people with cancer around the globe.
Our oncology focus includes:
Acute Lymphoblastic Leukemia
Acute lymphoblastic leukemia (ALL) is a cancer of the white blood cells characterized by an overproduction and accumulation of lymphoblasts, immature white blood cells. It is the most common type of cancer among children diagnosed with leukemia.
Pancreatic cancer is nearly always fatal. It is estimated that pancreatic cancer will become the second leading cause of cancer-related deaths worldwide by 2030.1 Fewer than 20% of patients with pancreatic cancer are diagnosed early enough to be eligible for surgery. Even with surgery, there is an 80% rate of recurrence. 2
- Rahib L, Smith B, Aizenberg R, et al. Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States. American Association for Cancer Research; 2014.
- Pancreatic Cancer Action Network Pancreatic Cancer Facts 2016, https://www.pancan.org/wp-content/uploads/2016/02/2016-GAA-PC-Facts.pdf